Shanghai Ovarian Cancer and Family Care Project

Ovarian Cancer Clinical Trial

Official title:

Shanghai Ovarian Cancer and Family Care Project

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06118307
• Other study ID #: KS23259
• Status: Recruiting
• Start date: January 1, 2013
• Est. completion date: October 13, 2028

Study information

• Verified date: October 2023
• Source: Shanghai First Maternity and Infant Hospital
• Contact: Yu Wang, MD; PhD
• Phone: 20261208
• Email: renjiwangyu[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Ovarian cancer is the most lethal gynaecological malignancy, but its incidence in the general population is low. Due to the lack of effective prevention and successful screening approaches, most cases are diagnosed at advanced stages, leading to poor prognosis. In order to address the research requirements pertaining to ovarian cancer, the Shanghai Ovarian Cancer and Family Care Project was established. This initiative offers hospital-based resources for investigating ovarian cancer and high-risk populations. The project comprises an on-going ovarian cancer cohort, a high-risk population cohort, and a healthy population cohort. By leveraging these comprehensive cohorts, the project provides a unique platform for in-depth studies on the detection, prevention, early diagnosis, treatment, and prognosis of ovarian cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3546
• Est. completion date: October 13, 2028
• Est. primary completion date: October 13, 2028
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Participant meet the criteria for one of the following conditions:

• Patients attending the oncology department require differential diagnosis of ovarian cancer.

• Patients with known high-risk factors for ovarian cancer, such as history of ovarian cancer or BRCA-associated cancer, etc.

• Patients attending the Physical Examination Center who have normal findings on physical examination and no symptoms.

Exclusion Criteria:

• Individuals with evidence of another active cancer.

• Individuals who have prior bilateral oophorectomy.

• Individuals who are unwilling or unable to sign the informed consent form.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Ovarian Cancer
• Ovarian Neoplasms

Locations

Country	Name	City	State
China	Shanghai first maternity and infant hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai First Maternity and Infant Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Death due to ovarian cancer	Death due to ovarian cancer determined by independent outcomes committee.	From diagnosis of ovarian cancer until October 31, 2028.